designed a micellar nanodrug carrier for delivering IκB kinase‐β (IKKβ) siRNA and STAT6 inhibitor AS1517499 (AS), and modified with a M2pep to target M2‐like TAMs for treatment of 4T1 breast tumor.[116] The resultant ST‐AS&Si nanodrug down‐regulated the expressions of IKKβ (a critical upstream factor controlling NF‐κB activation) and phospho‐STAT6 (p‐STAT6) in M2‐like macrophages, thereby repolarizing them into tumor‐killing M1 phenotype. The gene discussed is NFKB1; the disease is neoplasm.